NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOGRAFIN-60 is a diatrizoate meglumine injectable contrast agent used primarily for radiographic imaging procedures. It enhances visualization of blood vessels, organs, and body cavities during diagnostic imaging studies. The agent works by absorbing X-rays more readily than surrounding tissue, creating contrast in radiographic images.
LOE Approaching
As an aging product approaching loss of exclusivity, the brand team is likely focused on defending market share against generic and lower-cost alternatives in a commoditized contrast agent space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RENOGRAFIN-60 offers limited career advancement opportunities in a declining product category. Roles are primarily focused on operational efficiency, customer retention, and cost management rather than growth or innovation.
Brand ManagerSales Representative
Worked on RENOGRAFIN-60 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.